Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$34.3M Sell
64,675
-23,862
-27% -$11M 0.01% 927
2026
Q1
$42.5M Buy
88,537
+1,735
+2% +$888K 0.01% 724
2025
Q4
$48.8M Buy
86,802
+27,475
+46% +$15.6M 0.01% 654
2025
Q3
$30.5M Buy
59,327
+9,360
+19% +$4.09M 0.01% 879
2025
Q2
$15.7M Sell
49,967
-12,047
-19% -$3.62M ﹤0.01% 1243
2025
Q1
$18.9M Sell
62,014
-3,816
-6% -$1.28M 0.01% 1158
2024
Q4
$21.9M Sell
65,830
-2,044
-3% -$693K 0.01% 1137
2024
Q3
$22.7M Sell
67,874
-18,369
-21% -$6.98M 0.01% 1097
2024
Q2
$35.5M Sell
86,243
-14,941
-15% -$5.92M 0.01% 799
2024
Q1
$40.9M Buy
101,184
+735
+0.7% +$258K 0.01% 730
2023
Q4
$30.8M Buy
100,449
+4,676
+5% +$1.26M 0.01% 879
2023
Q3
$23.2M Buy
95,773
+18,201
+23% +$4.66M 0.01% 960
2023
Q2
$18.6M Sell
77,572
-51,651
-40% -$10.7M 0.01% 1114
2023
Q1
$24.3M Buy
129,223
+34,326
+36% +$7.1M 0.01% 908
2022
Q4
$20.2M Buy
94,897
+7,280
+8% +$1.45M 0.01% 1038
2022
Q3
$13.8M Sell
87,617
-5,071
-5% -$809K 0.01% 1272
2022
Q2
$13.9M Sell
92,688
-38,159
-29% -$5.52M 0.01% 1304
2022
Q1
$21.5M Sell
130,847
-12,533
-9% -$2.07M 0.01% 1162
2021
Q4
$29.3M Buy
143,380
+880
+0.6% +$184K 0.01% 998
2021
Q3
$26.5M Sell
142,500
-24,772
-15% -$4.52M 0.01% 1075
2021
Q2
$29.5M Sell
167,272
-22,652
-12% -$3.91M 0.01% 1083
2021
Q1
$31.2M Buy
189,924
+33,344
+21% +$5.1M 0.01% 1009
2020
Q4
$21.8M Buy
156,580
+66
+0% +$8.32K 0.01% 1204
2020
Q3
$17.5M Sell
156,514
-4,638
-3% -$536K 0.01% 1138
2020
Q2
$15M Sell
161,152
-4,443
-3% -$378K 0.01% 1224
2020
Q1
$12.2M Buy
165,595
+1,064
+0.6% +$92.4K 0.01% 1178
2019
Q4
$13.8M Sell
164,531
-239,479
-59% -$18.5M 0.01% 1394
2019
Q3
$34M Buy
404,010
+300,604
+291% +$22.7M 0.01% 856
2019
Q2
$6.76M Buy
103,406
+80,225
+346% +$4.62M ﹤0.01% 1827
2019
Q1
$1.37M Buy
23,181
+1,802
+8% +$108K 0.01% 694
2018
Q4
$1.13M Buy
+21,379
New +$1.17M 0.01% 698

Other funds holding MEDP

Nuveen's MEDP Position: Q2 2026 in Review

Nuveen reduced its Medpace (MEDP) stake by 27% in Q2 2026, selling an estimated $11M and leaving 64,675 shares worth $34.3M. The position accounts for 0.01% of the portfolio, ranked #927.

Nuveen first reported a position in MEDP in Q4 2018 and has held it in 31 quarters since. The position peaked at $48.8M in Q4 2025. 694 funds tracked by Wall St. Rank hold MEDP as of Q2 2026.

  • Nuveen held 64,675 shares of Medpace worth $34.3M as of Q2 2026.
  • Nuveen sold 23,862 Medpace shares in Q2 2026, an estimated $11M.
  • Medpace made up 0.01% of Nuveen's portfolio in Q2 2026, its #927 holding.
  • Nuveen first reported a position in Medpace in Q4 2018 and has held it in 31 quarters since.
  • Nuveen's Medpace position peaked at $48.8M in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Medpace as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.